Amylyx Pharmaceuticals, Inc. SEC filings AMLX
Amylyx Pharmaceuticals, Inc. has 440 filings in SEC EDGAR's recent list, going back to Nov 17, 2015. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 8, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 20, 2026 | Aug 19, 2026 |
| 424B5 | Prospectus supplement | Aug 20, 2026 | — |
| 424B5 | Prospectus supplement | Aug 18, 2026 | — |
| 8-K |
Current report
Other events
|
Aug 18, 2026 | Aug 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 18, 2026 | Aug 18, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 24, 2026 | Mar 24, 2026 |
| S-8 | Employee stock plan registration | Mar 3, 2026 | — |
| S-3ASR | Automatic shelf registration | Mar 3, 2026 | — |
| 10-K | Annual report | Mar 3, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 3, 2026 | Mar 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 8, 2026 | Jan 8, 2026 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Material agreement
|
Sep 10, 2025 | Sep 9, 2025 |
| 424B5 | Prospectus supplement | Sep 10, 2025 | — |
| 424B5 | Prospectus supplement | Sep 9, 2025 | — |
| 8-K |
Current report
Other events
|
Aug 27, 2025 | Aug 27, 2025 |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2025 | Jun 5, 2025 |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| ARS | Annual report to shareholders | Apr 24, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 24, 2025 | — |
| DEF 14A | Proxy statement | Apr 24, 2025 | Jun 5, 2025 |
| EFFECT | Filing | Mar 26, 2025 | — |
| CORRESP | Letter to the SEC | Mar 24, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 5, 2025 | — |
| S-8 | Employee stock plan registration | Mar 4, 2025 | — |
| S-3 | Shelf registration | Mar 4, 2025 | — |
| 10-K | Annual report | Mar 4, 2025 | Dec 31, 2024 |
| POSASR | Filing | Mar 4, 2025 | — |
| 8-K |
Current report
Results of operations
|
Mar 4, 2025 | Mar 4, 2025 |
| 8-K |
Current report
Material agreement
|
Jan 10, 2025 | Jan 10, 2025 |
| 424B5 | Prospectus supplement | Jan 10, 2025 | — |
| 424B5 | Prospectus supplement | Jan 10, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 30, 2024 | Dec 30, 2024 |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Other events
|
Oct 17, 2024 | Oct 17, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Acquisition or sale of assets
|
Jul 10, 2024 | Jul 9, 2024 |
| 8-K |
Current report
Material agreement
|
Jun 21, 2024 | Jun 21, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 6, 2024 | Jun 6, 2024 |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| ARS | Annual report to shareholders | Apr 24, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 24, 2024 | — |
| DEF 14A | Proxy statement | Apr 24, 2024 | Jun 6, 2024 |
| 8-K |
Current report
Other events
|
Apr 10, 2024 | Apr 10, 2024 |
| 8-K |
Current report
Exit or restructuring costs, Regulation FD disclosure, Other events
|
Apr 4, 2024 | Apr 3, 2024 |
| 8-K |
Current report
Officer or director change
|
Mar 14, 2024 | Mar 14, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 8, 2024 | Mar 8, 2024 |
| S-8 | Employee stock plan registration | Feb 22, 2024 | — |
| 10-K | Annual report | Feb 22, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 22, 2024 | Feb 22, 2024 |
| UPLOAD | Letter from the SEC | Dec 20, 2023 | — |
| CORRESP | Letter to the SEC | Dec 19, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 7, 2023 | Dec 7, 2023 |
| UPLOAD | Letter from the SEC | Dec 5, 2023 | — |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Other events
|
Oct 13, 2023 | Oct 13, 2023 |
| S-8 | Employee stock plan registration | Aug 10, 2023 | — |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Other events
|
Jul 26, 2023 | Jul 26, 2023 |
| 8-K |
Current report
Other events
|
Jun 23, 2023 | Jun 23, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2023 | Jun 8, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| ARS | Annual report to shareholders | Apr 27, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 27, 2023 | — |
| DEF 14A | Proxy statement | Apr 27, 2023 | Jun 8, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 21, 2023 | Mar 13, 2023 |
| S-8 | Employee stock plan registration | Mar 13, 2023 | — |
| S-3ASR | Automatic shelf registration | Mar 13, 2023 | — |
| 10-K | Annual report | Mar 13, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 13, 2023 | Mar 13, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 14, 2023 | Feb 14, 2023 |
| 8-K |
Current report
Material agreement
|
Dec 6, 2022 | Dec 1, 2022 |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Officer or director change
|
Nov 2, 2022 | Nov 1, 2022 |
| 424B4 | Prospectus | Oct 7, 2022 | — |
| EFFECT | Filing | Oct 6, 2022 | — |
| S-1MEF | Filing | Oct 6, 2022 | — |
| CORRESP | Letter to the SEC | Oct 4, 2022 | — |
| CORRESP | Letter to the SEC | Oct 4, 2022 | — |
| S-1 | Registration statement | Oct 4, 2022 | — |
| 8-K |
Current report
Other events
|
Sep 30, 2022 | Sep 30, 2022 |
| UPLOAD | Letter from the SEC | Aug 31, 2022 | — |
| DRS | Filing | Aug 24, 2022 | — |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 10-Q | Quarterly report | Aug 11, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 8-K |
Current report
Other events
|
Jul 5, 2022 | Jul 5, 2022 |
| 8-K |
Current report
Other events
|
Jun 13, 2022 | Jun 13, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2022 | Jun 9, 2022 |
| 8-K |
Current report
Other events
|
Jun 3, 2022 | Jun 3, 2022 |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 12, 2022 | May 12, 2022 |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 9, 2022 |
| 10-K | Annual report | Mar 31, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 31, 2022 | Mar 30, 2022 |
| S-8 | Employee stock plan registration | Jan 12, 2022 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jan 11, 2022 | Jan 11, 2022 |
| 424B4 | Prospectus | Jan 10, 2022 | — |
| SEC STAFF LETTER | Filing | Jan 6, 2022 | — |
| EFFECT | Filing | Jan 6, 2022 | — |
| S-1MEF | Filing | Jan 6, 2022 | — |
| CERT | Filing | Jan 6, 2022 | — |
| CORRESP | Letter to the SEC | Jan 4, 2022 | — |
| CORRESP | Letter to the SEC | Jan 4, 2022 | — |
| 8-A12B | Filing | Jan 4, 2022 | — |
| FWP | Free writing prospectus | Jan 4, 2022 | — |
| S-1/A | Amended registration statement | Jan 3, 2022 | — |
| CORRESP | Letter to the SEC | Dec 16, 2021 | — |
| S-1 | Registration statement | Dec 16, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 9, 2021 | — |
| SEC STAFF LETTER | Filing | Dec 1, 2021 | — |
| DRS/A | Filing | Nov 26, 2021 | — |
| DRSLTR | Filing | Nov 24, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 23, 2021 | — |
| DRSLTR | Filing | Oct 20, 2021 | — |
| DRS/A | Filing | Oct 20, 2021 | — |
| UPLOAD | Letter from the SEC | May 28, 2021 | — |
| DRS | Filing | Apr 26, 2021 | — |
| D | Filing | Jul 1, 2020 | — |
| D/A | Filing | Jan 28, 2020 | — |
| D/A | Filing | Dec 31, 2019 | — |
| D | Filing | Dec 31, 2019 | — |
| D | Filing | Nov 20, 2018 | — |
| D | Filing | Aug 4, 2017 | — |
| D/A | Filing | Aug 22, 2016 | — |
| D | Filing | Aug 22, 2016 | — |
| D/A | Filing | Nov 20, 2015 | — |
| D | Filing | Nov 17, 2015 | — |
Showing 151 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AMLX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1658551
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.